Moving Towards Precision Therapy for Patients with AML: Clinical Challenges and Future Directions

In this clinic-focused program review current and emerging strategies for personalizing AML treatment with expert-authored commentaries and an on-demand Webcast capturing expert discussion from the 2018 hematologic malignancies symposium in San Diego. Then download the meeting slidesets and decision support resources on prognostic factors and key AML clinical trials to help guide your AML treatment recommendations.

Share

Program Content

Activities

Targeting AML
The Importance of Molecular and Cytogenetic Targets in AML
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 12, 2018

Expires: September 11, 2019

Targeted AML Therapies
A New Paradigm: Targeted Therapies for Acute Myeloid Leukemia
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 15, 2018

Expires: October 14, 2019

ASH 2018: New AML Data
Promising Developments in AML From ASH 2018
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 27, 2018

Expires: December 26, 2019

Activities

Latest Treatments for AML
Moving Toward Precision Therapy for Patients With AML: Clinical Challenges and Future Directions
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2019

Expires: February 06, 2020

Activities

AML Prognostic Factors
At a Glance: Using Patient Prognostic Factors to Help Guide AML Treatment
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: November 27, 2018

Expires: November 26, 2019

AML Clinical Trials Guide
At a Glance: Select Phase III Clinical Trials for Acute Myeloid Leukemia
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: November 28, 2018

Expires: November 27, 2019

Activities

Antibody-based Tx in AML
Targeting Antigens in AML: New Advances in Antibody–Drug Conjugate and Other Antibody-Based Therapies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2018

Expires: December 03, 2019

Treating <i>FLT3</i> AML
Treating Patients With FLT3-Mutated Acute Myeloid Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2018

Expires: December 03, 2019

Emerging Agents in AML
Exploring New Therapeutic Frontiers in AML: Emerging Molecular Targets
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2018

Expires: December 04, 2019

ND AML: Optimal Treatment
Overcoming Treatment Challenges in Patients With Newly Diagnosed AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2018

Expires: December 04, 2019

Treating <i>IDH1/2</i> AML
Available and Emerging Treatment Options in IDH-Mutant AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2018

Expires: December 04, 2019

Faculty

cover img faculity

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

cover img faculity

Mark J. Levis, MD, PhD

Professor of Oncology
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

cover img faculity

Gary J. Schiller, MD

Professor
Division of Hematology/Oncology
Department of Medicine
Director, Hematological Malignancy/Stem Cell Transplantation
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Actinium

Astellas Text

Boston Biomedical

Celgene

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation